|
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
New targeted therapies for hematological malignancy include chimeric antigen receptor T cells (CAR T cells), Bi-specific T-cell Engager (BiTE) blinatumomab, and the antibody-drug conjugate (ADC) of calicheamicin inotuzumab ozogamicin for acute lymphoblasic leukemia (ALL) and lymphoma; the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib and phosphatidylinositol 3-kinase (PI3Kδ) inhibitor idelalisib for lymphoma and graft-versus-host disease (GVHD); FMS-like tyrosine kinase 3 (FLT3) inhibitors, such as midostaurin, sorafenib and gilteritinib for acute myeloid leukemia (AML); and the BCL-2 inhibitor venetoclax for a range of hematological malignancies including lymphoma and leukemia.
|
31688198 |
2019 |
|
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we evaluated the activity of acalabrutinib (ACP-196) and ACP-319 (AMG-319), second generation inhibitors of Bruton tyrosine kinase (BTK) and PI3Kδ inhibitor, respectively, in lymphoma pre-clinical models.
|
31355927 |
2019 |
|
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Bruton's tyrosine kinase (Btk) is a crucial regulator of B cell signaling and is a therapeutic target for lymphoma and autoimmune disease.
|
29483358 |
2018 |
|
Childhood Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This study expands the number of mutated genes described in several known signaling pathways and complexes involved in lymphoma pathogenesis (BCR, Notch, SWitch/sucrose nonfermentable (SWI/SNF), vacuolar ATPases) and identified novel recurrent mutations (EGR1/2, POU2AF1, BTK, ZNF608, HVCN1) that require further investigation in the context of FL biology, prognosis, and treatment.
|
28064239 |
2017 |
|
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
(S)-N-Boc-3-hydroxypiperidine ((S)-NBHP) is a key pharmaceutical intermediate and the chiral source in synthesizing Imbruvica, which is a newly approved drug in lymphoma therapy by targeting Bruton's tyrosine kinase (BTK).
|
27854034 |
2017 |
|
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, BCR signaling, activated in the lymph node microenvironment in vivo, appears to promote tumor proliferation and survival and may explain the sensitivity of this lymphoma to BTK inhibitors.
|
27127301 |
2016 |
|
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
More recently, point mutations conferring resistance to the Bruton tyrosine kinase inhibitor ibrutinib in chronic lymphocytic leukemia, arsenic trioxide in acute promyelocytic leukemia, and the BH3-mimetic ABT199 in lymphoma have been identified.
|
25795921 |
2015 |
|
Childhood Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We characterized these Btk mutant forms functionally by transfection into a lymphoma cell line that lacks endogenous Btk expression (Btk-/- DT40 cells) and analysed the calcium flux in response to B cell receptor stimulation.
|
18241233 |
2008 |
|
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Global gene expression profiling of the avian B-lymphoma DT40 cell-line was used as a model to differentiate among Btk knockout (KO) and Btk KO cells reconstituted with human Btk.
|
18930021 |
2008 |
|
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, BTK is the PTK responsible for triggering radiation-induced apoptosis of lymphoma B cells, and its kinase domain is indispensable for the apoptotic response.
|
8688094 |
1996 |